Business
Change of Adviser
Change of Adviser.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 9692V IXICO plc 12 April 2019 \n\n12 April 2019\n \nIxico plc\n \n(\"Ixico\" or \"the Company\")\n \nChange of Nominated Adviser & Sole Broker\n \nChange of adviser\nIXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, is pleased to announce the appointment, with immediate effect, of Cenkos Securities plc as its Nominated Adviser and sole broker.\n \nContacts\n\n\n\n\nIXICO plc\n\n\n+44 (0) 20 3763 7498\n\n\n\n\nGiulio Cerroni, Chief Executive Officer\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nCenkos Securities PLC (Nominated adviser and sole broker)\n\n\n+44 (0) 20 7397 8900\n\n\n\n\nGiles Balleny / Max Gould (Corporate Finance)\n\n\n \n\n\n\n\nMichael F Johnson / Russell Kerr (Sales)\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nOptimum Strategic Communications\n\n\n +44 (0) 203 950 9144\n\n\n\n\nMary Clark / Anne Marieke Ezendam / Supriya Mathur\n\n\n \n\n\n\n\[email protected]\n\n\n \n\n\n\n\n \nAbout IXICO \nIXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel medical imaging and mobile health digital technologies.\n \nIXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes. www.ixico.com\n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.r...